Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC294640 in Refractory/Relapsed DLBCL or Kaposi Sarcoma
NCT02229981Phase 2Withdrawn
- Sponsor
- RedHill Biopharma
- Start
- Jul 2014
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Opaganib in diffuse large B-cell lymphoma (DLBCL), Kaposi sarcoma (KS), sponsored by RedHill Biopharma. Planned start Jul 2014; status: withdrawn.
02
Drugs
Opaganib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT02229981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229981.